

## HR 9321

### Independent Drug Value Assessment Act

**Congress:** 117 (2021–2023, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Nov 16, 2022

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Nov 17, 2022)

**Official Text:** <https://www.congress.gov/bill/117th-congress/house-bill/9321>

### Sponsor

**Name:** Rep. Speier, Jackie [D-CA-14]

**Party:** Democratic • **State:** CA • **Chamber:** House

### Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Nadler, Jerrold [D-NY-10]	D · NY		Nov 16, 2022
Rep. Porter, Katie [D-CA-45]	D · CA		Nov 16, 2022

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Nov 17, 2022

### Subjects & Policy Tags

#### Policy Area:

Health

### Related Bills

No related bills are listed.

### Summary (as of Nov 16, 2022)

### Independent Drug Value Assessment Act

This bill requires the Office of the Assistant Secretary for Planning and Evaluation to contract with outside entities to conduct independent value assessments of approved drugs (i.e., economic analysis of the benefits to patients and the health care system).

### Actions Timeline

- **Nov 17, 2022:** Referred to the Subcommittee on Health.
- **Nov 16, 2022:** Introduced in House
- **Nov 16, 2022:** Referred to the House Committee on Energy and Commerce